<DOC>
	<DOC>NCT00592904</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability and continued efficacy of perampanel in patients previously enrolled in double-blind, placebo-controlled studies for Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN).</brief_summary>
	<brief_title>Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Neuralgia, Postherpetic</mesh_term>
	<criteria>Each patient must meet all of the following criteria to be enrolled in this study: 1. Met and continues to meet all inclusion and none of the exclusion criteria for the preceding PDN or PHN study and received study drug or placebo under doubleblind conditions. 2. Completed the preceding doubleblind study End of Treatment (EOT) Visit no more than 12 weeks prior to Baseline (Visit 1) for the openlabel study. The eligibility status of patients who do not enroll during this 12 week period will be evaluated on a case by case basis via discussion between the Investigator and the Sponsor. 3. Males and females â‰¥18 years of age. Female patients should be either of nonchildbearing potential as a result of surgery or menopause (1 year after onset), or of childbearing potential and practicing a medically acceptable method of contraception (e.g., abstinence, a barrier method plus spermicide, or intrauterine device [IUD]) for at least 1 month before the Baseline Visit (Visit 1) and for 1 month after the end of the study (Visit 16). They must also have a negative pregnancy test at Baseline (Visit 1). Female patients using hormonal contraceptives must also be using an additional approved method of contraception (e.g., a barrier method plus spermicide or IUD) throughout the study. 4. Provide written informed consent prior to entering the study and prior to undergoing any studyrelated procedures. 5. Is reliable, willing, and able to cooperate with the study procedures. Patients who meet the following criterion will be excluded from this study: 1. Patients who discontinued early for any reason from the preceding doubleblind study. 2. Patients who have a clinically significant finding(s) that would make them unsuitable for the study in the opinion of the investigator or Sponsor.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Neuralgia</keyword>
	<keyword>neuropathy</keyword>
</DOC>